Nov. 16, 2023
The Centers for Medicare and Medicaid Services (CMS) recently updated the FAQ for the use of JW and JZ modifiers. Beginning Oct. 1, CMS required the use of JW and JZ modifiers for all claims for drugs from single-use vials or single-use packages payable separately under Medicare Part B. The JW modifier is used to identify any discarded amounts. The JZ modifier is used to attest that there were no discarded amounts. CMS also posted a (non-exhaustive) list of codes subject to the modifier policy.

The American College of Radiology®(ACR®), the Radiology Business Management Association, RadNet, and RayUS met with CMS in September and advocated for the exclusion of imaging contrast agents and radiopharmaceuticals from the JW/JZ reporting requirement. CMS did however indicate the list likely will be updated semi-annually with newly identified codes.

If you have any questions, contact Christina Berry, ACR Team Lead, Economic Policy.

Related ACR News

  • Focus on Scope: Latest Status of State Healthcare-Related Bills

    Overview of status of several bills in this year’s state legislative sessions related to scope of practice.

    Read more
  • Participate in the Healthcare AI Challenge at ACR 2025

    Call for ACR 2025 attendees to participate in healthcare AI challenge at the upcoming meeting.

    Read more
  • Supreme Court Hears Oral Arguments in Kennedy vs. Braidwood Case

    ACR is monitoring the Kennedy vs. Braidwood Management case, which could potentially affect full insurance coverage of at least some cancer screening exams.

    Read more